Covaxin Problem of Indian students who received Covaxin raised with US
New Delhi/IBNS: India has raised the concerns of students vaccinated with indigenously developed Covaxin and planning a return to US educational institutions during a meeting between foreign secretary Harsh Shringla and US chargé d’ affaires Daniel Smith, said a Hindustan Times report.
Foreign Secretary @harshvshringla had a productive meeting today with US Acting Ambassador Daniel B. Smith @USAmbIndia about India-US relations, regional issues & cooperation in the UN; also discussed Covid19 situation, supply of vaccines & cooperation in combating the pandemic.
Foreign Secretary @harshvshringla had a productive meeting today with US Acting Ambassador Daniel B. Smith @USAmbIndia about India-US relations, regional issues & cooperation in the UN; also discussed Covid19 situation, supply of vaccines & cooperation in combating the pandemic. pic.twitter.com/UnxCz4xlZ8
— Arindam Bagchi (@MEAIndia) June 9, 2021
Hindustan Times report said citing sources that the issue of travel by Indian students vaccinated with the indigenously developed Covaxin vaccine, which is yet to receive approval from World Health Organization (WHO), was raised by Shringla.
The sources stated that Smith assured to convey India’s concerns to US authorities, the report added.
Covishield, which has been jointly developed by AstraZeneca and Oxford University and manufactured in India by Serum Institute of India (SII), has been approved by WHO for emergency use.
As the US is easing restrictions, many US universities are planning regular classrooms for the students from August.
The CDC website says that foreign travellers and students will be considered fully vaccinated if two weeks have elapsed after the second dose of a two-dose vaccine, or two weeks after a single-dose vaccine. “If you don’t meet these requirements, you are NOT fully vaccinated,” the guidelines state.
Of the vaccines used in India, the CDC approves only the AstraZeneca jab which is available in India as Covishield and Covain is not approved by it.
Indian students vaccinated with Covaxin and planning to join campuses in US and Europe have raised the issue with the government, especially the External Affairs Ministry, said the report.
Bharat Biotech, the maker of Covaxin, will provide additional documents for WHO’s emergency use listing of the vaccine by June.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
